Spinal Cord Injury Market

Market Overview:

The 7 major spinal cord injury markets are expected to exhibit a CAGR of 4.06% during 2024-2034.

The spinal cord injury market has been comprehensively analyzed in IMARC's new report titled "Spinal Cord Injury Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A spinal cord injury refers to damage or trauma to the spinal cord, which is a long, cylindrical bundle of nerves that extends from the base of the brain down the back. The symptoms of the ailment can vary depending on the level and severity of the injury but commonly include loss of sensation, muscle weakness or paralysis, altered reflexes, impaired coordination, changes in bowel and bladder function, sexual dysfunction, difficulty breathing, chronic pain, etc. In more severe cases, individuals suffering from the condition may experience complete paralysis below the injury site, while in milder instances, there may be partial loss of function or sensory deficits. The diagnosis typically begins with a thorough medical history review and a physical examination to assess neurological function, sensory responses, and motor strength. Numerous diagnostic imaging techniques, such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), etc., may be used to visualize the spinal cord and determine the extent and location of the injury. Furthermore, various additional tests, including electromyography (EMG), nerve conduction studies, somatosensory evoked potentials (SSEP), etc., are also conducted to evaluate nerve function and assess the severity of the injury.

The increasing cases of traumatic injuries resulting from motor vehicle mishaps, falls, sports-related accidents, acts of violence, etc., that can fracture or dislocate the vertebrae are primarily driving the spinal cord injury market. In addition to this, the rising incidences of various associated risk factors, including surgical complications, certain medical conditions like spinal tumors and spinal abscesses, genetic disorders, such as hereditary spastic paraplegia, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of neuroprotective agents, including methylprednisolone and minocycline, since they aid in reducing inflammation, promote cell survival, and minimize scar formation, is further bolstering the market growth. Apart from this, the rising utilization of advanced rehabilitation approaches, such as activity-based therapies, constraint-induced movement therapy, virtual reality-based training, etc., for enhancing motor recovery and promoting neural plasticity is acting as another significant growth-inducing factor. Additionally, the emerging popularity of neural interface systems, including brain-computer interfaces and spinal cord stimulation, to bridge the damaged spinal cord circuitry in order to facilitate communication between the brain and limbs is expected to drive the spinal cord injury market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the spinal cord injury market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for spinal cord injury and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spinal cord injury market in any manner.

Recent Developments:

• In February 2024, Kringle Pharma released topline data from a nonrandomized, multicenter, confirmatory Phase 3 research on KP-100IT, an intrathecal formulation of recombinant human hepatocyte growth factor, in individuals with acute spinal cord injury. Based on the findings of this trial and the earlier Phase 1/2 study, KRINGLE will carry on its conversation with the Japanese regulatory body and get ready to apply for approval to manufacture and market products in Japan.

Key Highlights:

• The annual incidence of spinal cord injuries is 15–40 cases per million people worldwide.
• Epidemiological studies estimate that there are around 18,000 acute spinal cord injury episodes in the United States each year.
• Spinal cord injury impacts men more than women.
• The age range with the highest risk of spinal cord injury is 16 to 30 years old.
• Research indicates that individuals with a spinal cord injury die earlier than those without a spinal cord injury and are 2 to 5 times more probable to die prematurely.

Drugs:

Stemirac Inj is a mesenchymal stem cell therapy product developed by Nipro Corporation to treat spinal cord injury. It is derived from the patient's bone marrow fluid and peripheral blood. Stemirac is delivered via intravenous injection.

AXER-204 is under clinical development by ReNetX Bio for the treatment of spinal cord injury. It functions as a decoy receptor, binding to myelin-associated inhibitors of axonal growth and allowing the body to produce nerve fibres.

MT-3921 is a monoclonal antibody being developed by Mitsubishi Tanabe Pharma Corporation (MTPC) and Osaka University to treat spinal cord injury. The humanized immunoglobulin G1 antibody interacts with the repulsive guidance molecule A.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the spinal cord injury market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the spinal cord injury market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current spinal cord injury marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the spinal cord injury market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the spinal cord injury market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the spinal cord injury market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of spinal cord injury across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of spinal cord injury by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of spinal cord injury by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with spinal cord injury across the seven major markets?
• What is the size of the spinal cord injury patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of spinal cord injury?
• What will be the growth rate of patients across the seven major markets?
   

Spinal Cord Injury: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for spinal cord injury drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spinal cord injury market?
• What are the key regulatory events related to the spinal cord injury market?
• What is the structure of clinical trial landscape by status related to the spinal cord injury market?
• What is the structure of clinical trial landscape by phase related to the spinal cord injury market?
• What is the structure of clinical trial landscape by route of administration related to the spinal cord injury market?